FEBS-40 TAB

About

Febuxostat is a non-purine selective inhibitor of xanthine oxidase, the enzyme responsible for the production of uric acid. By inhibiting xanthine oxidase, febuxostat effectively reduces serum uric acid levels, which is crucial in the management of chronic hyperuricemia in patients with gout. Unlike allopurinol, febuxostat is not a purine analogue and has a different metabolic pathway, offering an alternative treatment option.

This medication is indicated for the long-term treatment of hyperuricemia in adult patients with gout. It helps to prevent gout flares and can lead to the dissolution of urate crystals over time, thereby reducing the frequency and severity of gout attacks and preventing joint damage. Regular monitoring of uric acid levels is essential during treatment to ensure therapeutic efficacy and safety.

Uses

• Long-term management of chronic hyperuricemia in gout patients.
• Prevention of gout flares.
• Reduction of serum uric acid levels.
• Dissolution of urate crystals over time.

Directions For Use

Take this medication orally once daily, with or without food, as directed by your doctor. Do not stop taking it without consulting your physician.

Benefits

• Effectively lowers serum uric acid levels.
• Non-purine selective xanthine oxidase inhibitor.
• Reduces frequency of gout flares.
• Can lead to dissolution of urate crystals.
• Convenient once-daily dosing.
• Alternative for patients intolerant to allopurinol.

Side Effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Rash
• Abnormal liver function tests
• Gout flares (initial)
• Arthralgia
• Muscle pain
• Fatigue
• Edema
• Cardiovascular events (rare, but noted in some studies)

Safety Measures

• Alcohol - Alcohol consumption, particularly beer and spirits, can increase uric acid levels and trigger gout flares. It is advisable to limit or avoid alcohol while on febuxostat.
• Pregnancy - Not recommended during pregnancy due to insufficient data on human pregnancy and potential risks. Use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is unknown if febuxostat is excreted in human breast milk. A decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.
• Liver - Use with caution in patients with mild to moderate liver impairment. Regular monitoring of liver function tests is recommended, and it is contraindicated in severe hepatic impairment.
• Kidney - Dose adjustment is not typically required for mild to moderate renal impairment, but caution is advised in severe renal impairment.
• Lung - No specific contraindications or special precautions related to pre-existing lung conditions are generally noted for febuxostat.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.